A Pilot Study Assessing the Ability of Bemcentinib to Get into Brain Tumors in Patients with Recurrent Glioblastoma Who Need Surgery


Full Title

Pilot Surgical PK Study of Bemcentinib in Recurrent Glioblastoma Patients (CIRB)


The purpose of this study is to determine how much the drug called bemcentinib (BGB324) gets into a brain tumor and how well it works to treat patients with glioblastoma that has come back and requires surgery. BGB324 is a drug called an AXL inhibitor. It may stop the growth of tumor cells by blocking some of the enzymes needed for cancer cell growth.

 One group of patients will receive bemcentinib before surgery as well as after surgery, and the second group of patients will receive bemcentinib only after surgery. It is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have glioblastoma that came back after prior radiation therapy and/or chemotherapy and requires surgery.
  • No more than two prior relapses are permitted.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Thomas Kaley at 212-639-5122 or the Brain Tumor Hotline at 866-886-9807.





Disease Status

Relapsed or Refractory